explore -WSS

explore

author：entertainment 2025-09-02 08:19:57 - browse：3

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Laying a path for careers in science

explore

knowledge

WSS

Cholera vaccine supplies dangerously low, outbreaks surging

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Election results set back Medicaid expansion plans

How CRISPR works, explained in two minutes

How CRISPR works, explained in two minutes

CDC panel: People 65 and older should get a Covid spring booster shot

hotspot

explore

leisure time

What does generative AI mean for health care? We asked experts

Kansas bar where gunfire wounded 9 last month closes permanently

Activists slam private health insurers over coverage restrictions

Redefining sustainability for the pharmaceutical industry

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Are embryos people? Reproductive medicine's future depends on the answer

As demand for Covid shots wanes, Moderna seeks its next success

5 ways to address the shortage of health care workers

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare Advantage isn’t working — for anyone

hotspot

Failure, not just success, should guide future doctors

Neuroscience renaissance leads to new crop of psychiatric drugs

CDC panel: People 65 and older should get a Covid spring booster shot

Virtual repurposing can help discover new uses for existing drugs

Failure, not just success, should guide future doctors

Color Health wants to make cancer screenings convenient

explore

knowledge

explore

focus